COCP News and Press, Cocrystal Pharma Inc. From 02/25/20

VivoPower International PLC (NASDAQ: VVPR ) +57%  on 1H results . More news on: VivoPower International PLC, Cocrystal Pharma, Inc., Mallinckrodt plc, Stocks on the move, , Read more ...

BOTHELL, WA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used to further develop leads and choose clinical candidate - COCRYSTAL PHARMA, INC. (NASDAQ: C...

     –   Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral diseases, including coronavirus respiratory infections – ...

– Presentation on Tuesday, February 18 th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”) , a clinical stage biotechnology company discovering and develo...

Are These Penny Stocks On Your Watch List Right Now? Generally speaking, most new investors do not often have a big budget at the start of their investing journey. Now, this isn’t always the case and “budget” is subjective to who you speak to. Some people may consider $1,0...

BOTHELL, WA, Feb. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”) , a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the closing of it...

BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”) , a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the pricing of a ...

– Presentation on Tuesday, December 10 th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .  (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company di...

Cocrystal Pharma (NASDAQ: COCP ): Q3 GAAP EPS of -$0.06. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) –  – Preclinical influenza A/B program fully-funded by development and commerci...